Jiangsu Hengrui Medicine Co., Ltd
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 1970-01-01
- Employees
- -
- Market Cap
- $38.9B
Phase I/II Clinical Study of FH-006 for Injection in Patients With Malignant Solid Tumors
- First Posted Date
- 2024-12-16
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 200
- Registration Number
- NCT06735144
A Study for Adults Undergoing Magnetic Resonance Imaging (MRI) for Known or Highly Suspected Brain and/or Spinal Cord Conditions
Phase 2
Not yet recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-12-12
- Last Posted Date
- 2024-12-12
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 78
- Registration Number
- NCT06731829
- Locations
- 🇨🇳
People's Hospital, Peking University, Peking, Beijing, China
Investigation of Drug-drug Interaction of Ritonavir and Itraconazole on the Pharmacokinetics of SHR-A1811 in Subjects With HER2-expressing Advanced Breast Cancer
Phase 1
Not yet recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-12-02
- Last Posted Date
- 2024-12-02
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 32
- Registration Number
- NCT06710990
- Locations
- 🇨🇳
Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China
Efficacy and Safety of SHR-3167 and Insulin Glargine in Type 2 Diabetes Subjects
- First Posted Date
- 2024-11-14
- Last Posted Date
- 2024-11-14
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 273
- Registration Number
- NCT06688123
- Locations
- 🇨🇳
Jiangsu Provincial People's Hospital, Nanjing, Jiangsu, China
🇨🇳Shanghai Sixth People's Hospital, Shanghai, Shanghai, China
A Study for the Treatment of Metastatic Prostate Cancer With HRS-1167 Tablets Combined With Abiraterone Acetate Tablets and Prednisone
Phase 1
Not yet recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-11-14
- Last Posted Date
- 2024-11-14
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 66
- Registration Number
- NCT06689163
- Locations
- 🇨🇳
The First Affiliated Hospital Of Anhui Medical University, Hefei, Anhui, China
🇨🇳Hunan Cancer Hospital, Changsha, Hunan, China
The Experiment of Noiiglutide Injection in Type 2 Diabetes Patients
Phase 3
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-10-21
- Last Posted Date
- 2024-11-14
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 124
- Registration Number
- NCT06649773
- Locations
- 🇨🇳
Beijing Chaoyang Hospital Affiliated to Capital, Beijing, Beijing, China
Pharmacokinetics,Pharmacodynamics,Efficacy and Safety of HRG2010 in Parkinson's Disease Patients With Motor Fluctuations
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2024-09-26
- Last Posted Date
- 2024-09-26
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 61
- Registration Number
- NCT06614153
- Locations
- 🇨🇳
Beijing Hospital, Beijing, Beijing, China
A Study to Evaluate the Efficacy and Safety of HRG2010 in Parkinson's Disease With Motor Fluctuations
Phase 3
Not yet recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-09-19
- Last Posted Date
- 2024-09-19
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 450
- Registration Number
- NCT06596876
- Locations
- 🇨🇳
Beijing Hospital, Beijing, Beijing, China
A Clinical Study of the Safety, Tolerability, Pharmacokinetics, and Initial Efficacy of HRS-4508 Monotherapy in Patients With Advanced or Metastatic Solid Tumors
- First Posted Date
- 2024-09-19
- Last Posted Date
- 2024-09-19
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 100
- Registration Number
- NCT06598735
- Locations
- 🇨🇳
Cancer Hospital Chinese Academy of Medical Sciences, Beijing, Beijing, China
A Study of HRS-5041 Tablets Combined With Antitumor Therapy in Subjects With Advanced Prostate Cancer
- First Posted Date
- 2024-08-23
- Last Posted Date
- 2024-10-23
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 100
- Registration Number
- NCT06568094
- Locations
- 🇨🇳
The Second Affiliated Hospital of Harbin Medical University, Ha'erbin, Heilongjiang, China
🇨🇳Shanghai Jiao Tong University School of Medicine, Renji Hospital, Shanghai, Shanghai, China
© Copyright 2024. All Rights Reserved by MedPath